Peter Svennilson founded The Column Group (TCG) in 2007, a biotech VC group based in San Francisco with $3.5B in commitments that has started and invested in 45 biotech companies so far. He has worked in venture capital and finance for 37 years. He was the Chairman of Aragon from startup until it was sold to Johnson & Johnson in 2013 and was the Chairman of Seragon until it was sold to Genentech/Roche in 2014.
Mr. Svennilson currently serves as a Board Director of Carmot and Escient. He has been a Board Director of biotech companies such as: NGM (“NGM”), Constellation (“CNST”), Revolution Medicine (“RVMD”), RAPT (“RAPT”), ORIC (“ORIC”), Immune Design (“IMDZ”), Rosetta (“RSTA”), PTC (“PTCT”), Chemocentryx (“CCXI”), Tercica (“TRCA”) and Somalogic (“SLGC”). He was also a Board Observer of Arcus (“RCUS”).
Prior to TCG, he was the Founder and Managing Partner of Three Crowns Capital where he helped found and/or finance large parts of the venture capital for biotech companies such as: Tularik (“TLRK”), Rosetta (“RSTA”), PTC (“PTCT”), Chemocentryx (“CCXI”), Rinat, Tercica (“TRCA”), Somalogic (“SLGC”), Infinity (“INFI”) and Fiveprime (“FPRX”).
Prior to Three Crowns Capital, he was the Associate Managing Director in charge of European Investment Banking Origination for Nomura in Europe.
Mr. Svennilson is a Trustee at The Institute for Advanced Study in Princeton. He received an MBA from the Stockholm School of Economics with further studies at the MBA programs at INSEAD in Fontainebleau and London Business School.